8-K: Calidi Biotherapeutics Announces CEO Transition: Eric Poma Appointed as New CEO and Director

Calidi Biotherapeutics appoints Eric Poma as CEO and Director, succeeding Allan Camaisa who will remain on the Board, effective April 22, 2025.

Summary

• Calidi Biotherapeutics announced that Allan Camaisa will transition from CEO to CEO Emeritus and remain on the Board of Directors.
• Eric Poma, Ph.D., has been appointed as the new CEO and a member of the Board, effective April 22, 2025.
• Mr. Camaisa's resignation is not due to any disagreement with the company.
• Mr. Camaisa will receive $500,000 in separation pay over 12 months, COBRA premiums for 12 months, and $10,000 per month in transition/consulting pay.
• Mr. Camaisa may also be entitled to incentive payments based on revenues, capital, or monies actually received by the Company on or before December 31, 2026, related to opportunities he developed.
• Dr. Poma's employment agreement includes an annual base salary of $535,000 and eligibility for an annual bonus of up to 50% of his base salary.
• Dr. Poma will receive a stock option to purchase 726,412 shares of common stock, vesting over four years.
• James Schoeneck has been appointed as Chairman of the Board, effective April 22, 2025.
• The Board increased its size from five to six members following Dr. Poma's appointment.
• Dr. Poma previously served as CEO of Molecular Templates, where he raised over $250 million in equity financing and secured over $150 million in strategic capital through agreements with Takeda, Vertex and BMS.

Sentiment

Score: 7

Explanation: The announcement is generally positive, highlighting a smooth leadership transition and the appointment of an experienced CEO. The company is progressing with its clinical programs, and management expresses confidence in the future.

Positives

• The transition appears amicable, with Allan Camaisa remaining on the Board.
• Eric Poma brings extensive experience in the biopharmaceutical industry, including capital fundraising and clinical program development.
• Dr. Poma's previous role as CEO of Molecular Templates involved raising significant capital and securing strategic agreements.
• The company is progressing with its clinical and preclinical programs.
• The company secured its first company-sponsored FDA approved IND for CLD-201.

Negatives

• The company will incur separation costs of $500,000 plus benefits for the outgoing CEO.
• The company will pay $10,000 per month in transition/consulting pay to the outgoing CEO.
• The company is paying legal fees of up to $10,000 for the outgoing CEO.
• The company is paying legal fees for the incoming CEO.

Risks

• The transition of leadership could create uncertainty within the company.
• The success of Dr. Poma in his new role is crucial for the company's future performance.
• The company's ability to advance its clinical programs depends on raising sufficient capital.
• Clinical trial results are uncertain and may not lead to FDA approval.
• The company's reliance on stem cell-based platforms and oncolytic viruses carries inherent risks associated with novel therapies.

Future Outlook

Calidi Biotherapeutics anticipates advancing its systemic enveloped virotherapy platform to the clinic and preparing for a company sponsored, dose escalation trial of CLD-201 in adult patients with solid tumors.

Management Comments

• James Schoeneck stated that Eric Poma's experience in life science leadership with a focus on oncology is valuable as Calidi advances its systemic enveloped virotherapy platform.
• Eric Poma expressed excitement about joining Calidi and leveraging his experience to drive and increase shareholder value.
• Allan Camaisa stated that he is proud to have achieved the first company-sponsored FDA approved IND for CLD-201 and is confident and excited about Calidi's future under Eric's leadership.

Industry Context

The appointment of Eric Poma, with his experience in securing financing and collaboration agreements, suggests a focus on strategic partnerships and financial growth for Calidi Biotherapeutics in the competitive immuno-oncology space.

Comparison to Industry Standards

• Eric Poma's previous role as CEO of Molecular Templates (NASDAQ: MTEM) involved raising over $250 million in equity financing and securing over $150 million in strategic capital through agreements with Takeda, Vertex and BMS.
• This level of fundraising and collaboration is comparable to other clinical-stage biotechnology companies focused on novel therapeutic platforms.
• The base salary of $535,000 for the new CEO is within the typical range for CEOs of publicly traded biotechnology companies of similar size and stage.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders may react positively to the appointment of an experienced CEO with a track record of fundraising and business development.
• Employees may experience uncertainty during the leadership transition, but the company aims to maintain stability.
• Customers and partners may benefit from the company's continued progress in developing novel cancer therapies.

Next Steps

• Eric Poma will assume his role as CEO and director, effective April 22, 2025.
• Calidi will continue to advance its clinical and preclinical programs.
• The company will prepare for a company-sponsored, dose escalation trial of CLD-201 in adult patients with solid tumors.
• Allan Camaisa will continue to serve as a member of the Board and CEO Emeritus.

Key Dates

Keywords

CEO transition, Eric Poma, Allan Camaisa, Calidi Biotherapeutics, biotechnology, virotherapy, oncology, leadership, appointment, resignation